15.9.2009


VTT Newsletter

05 | 2009
Dear recipient, VTT´s electronic newsletter has been revised. It consists of the latest news releases concerning research, science, technology and business applications. In addition to these, we inform you about the newest publications and other current topics. The links will take you to VTT's website.

You can subscribe to or unsubscribe from the list in address: http://www.vtt.fi/newsletter_subscribe.htm

 Science - impact - potential of technology
VTT launches large European cooperation project for developing manufacturing method for biofuel
VTT Technical Research Centre of Finland has started a large European project, combining the forces of European research institutes and companies for developing the next generation of biofuel. The NEMO project, which has received funding of EUR 5.9 million from the EU, is aimed at developing manufacturing methods for liquid biofuel from agricultural and forestry waste, such as straws and wood chips.
 
 
Researchers of VTT, the University of Turku and the University of Heidelberg discover new information on spreading of cancer
A joint research group of VTT Technical Research Centre of Finland and the University of Turku, led by Professor Johanna Ivaska, has discovered a mechanism lung cancer cells use when spreading into the body to form metastases. The study has been published in Science Signaling on 30th June 2009. In cooperation with the University of Heidelberg, they have also found a factor controlling the spreading of several different cancer types. The common feature in both findings is that they explain the lethal ability of cancer cells to “start running” and spread from the original tumour to other parts of the body.
 
 
 Business from technology - applications
VTT starts to investigate Bayer Schering Pharma’s preclinical anti-cancer compounds
VTT Technical Research Centre of Finland and Bayer Schering Pharma AG, Germany have signed a two-year research contract to study the mode of action of a Bayer Schering Pharma’s preclinical cancer drugs. As part of this contract, VTT will use its new gene and cancer biology methods such as the 3D-cell culture model developed at VTT’s Medical Biotechnology unit in Turku, Finland.
 
  Other topical
New publications
Innovation Excellence Master Class, 27-29 October, 2009

Copyright VTT 2009 • Address: P.O. Box 1000, FI-02044 VTT • Tel: +358 20 722 111 • Fax: +358 20 722 7001 • info@vtt.fi